Clinical Trial

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.
Protocol Amendment History 2 changes
notable Enrollment reduced: 480 -> 410 participants 2026-05-30
critical Recruitment opened 2026-05-09
Trial Details
NCT Number NCT07480733
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Advanced Malignant Solid Tumors
Enrollment 410 participants
Start Date 2026-04-23
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-11-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-29